Diagnostic utility of serum anti-Mullerian hormone levels in south Indian women with polycystic ovarian syndrome

Naveetha Lakshmi Narayanaswamy; Freethi Ramanathan; Moonishaa Thiyagarajan Manjuladevi

doi:10.51248/.v43i4.2312

Authors

Naveetha Lakshmi Narayanaswamy
Freethi Ramanathan
Moonishaa Thiyagarajan Manjuladevi

DOI:

https://doi.org/10.51248/.v43i4.2312

Keywords:

Anti-müllerian hormone, Polycystic ovarian syndrome, Rotterdam criteria, antral follicular count, ovarian volume

Abstract

Introduction and Aim: Polycystic ovarian syndrome (PCOS) is a prevalent endocrinopathy among women of reproductive age group, conventionally diagnosed using multiple clinical and biochemical tests. We aimed to evaluate the diagnostic utility of serum anti-Müllerian hormone (AMH) levels in PCOS.

Materials and Methods: The case control study involved 60 women of 18-40 years age, further grouped using Rotterdam criteria as cases with PCOS (n = 30) and controls without PCOS (n = 30). Study variables were compared between the groups using independent t-test. Correlation analyses were performed to predict the relationship of AMH with other PCOS determinants. Simple logistic regression and ROC analyses were used to determine the diagnostic utility of AMH.

Results: PCOS cases had increased levels of serum LH, testosterone, AMH, BMI, total antral follicular count (AFC), ovarian volume (OV) (p < 0.05*) than controls. Of all, serum AMH had the strongest association with PCOS (OR > 1, p < 0.05*) and showed considerable positive correlations with LH:FSH ratio, testosterone, AFC (r = 0.7768, p < 0.05*), OV (r = 0.7981, p < 0.05*). ROC analysis of AMH was significant (AUC = 0.966, p < 0.05*) with high sensitivity, specificity for cut points between 5.595 ng/mL and 5.90 ng/mL.

Conclusion: Elevated serum AMH levels were strongly associated with PCOS and correlated with its routine clinical determinants. Serum AMH estimation with cut-off between 5.595 ng/mL to 5.90 ng/mL, is proposed as a useful index for PCOS diagnosis.

Author Biographies

Naveetha Lakshmi Narayanaswamy

Department of Biochemistry, Dhanalakshmi Srinivasan Medical College and Hospital, (Affiliated to The Tamil Nadu Dr.M.G.R Medical University), Siruvachur, Perambalur, 621 212, Tamil Nadu, India

Freethi Ramanathan

Department of Biochemistry, K.A.P. Viswanatham Government Medical College, (Affiliated to The Tamil Nadu Dr.M.G.R Medical University), Periyamilaguparai, Trichy - 620 001, Tamil Nadu, India

Moonishaa Thiyagarajan Manjuladevi

Department of Biochemistry, Srinivasan Medical College and Hospital, (Affiliated to Dhanalakshmi Srinivasan University), Samayapuram, Trichy, 621 112, Tamil Nadu, India

References

Hegde P, Shetty PK, Shetty SS, Manjeera L, Shetty DP. A study on changes in hormonal disruption in polycystic ovary syndrome with advancing age and body mass index. Biomedicine. 2022 Jul 3;42(3):461-8.

Auda SA, Gatea EA, Radhi ZA. Evaluation of thyroid autoimmunity markers in polycystic ovarian syndrome in women. Biomedicine. 2023 Jul 1;43(3):893-6.

Wu, S., Divall, S., Nwaopara, A., Radovick, S., Wondisford, F., Ko, C., et al., Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014;63:1270-1282.

Lavanya K, Palaniappan N, Vinodhini VM, Kumar M, Silambanan S. Association of prolactin and insulin with obesity in women with polycystic ovarian syndrome. Biomedicine. 2022 Dec 31;42(6):1166-71.

Dev D, Dutta P. A novel approach to treat polycystic ovarian syndrome (PCOS) patients. Biomedicine. 2022 Sep 12;42(4):841-3.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.

Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., Azziz, R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6-15.

Moolhuijsen, L.M.E., Visser, J.A. Anti-Müllerian hormone and ovarian reserve: Update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105:3361-3373.

Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114:1151-1157.

Cook, C.L., Siow, Y., Brenner, A.G., Fallat, M.E. Relationship between serum Müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77:141-146.

Parahuleva, N., Pehlivanov, B., Orbecova, M., Deneva, T., Uchikova, E. Serum levels of anti-Mullerian hormone in women with polycystic ovary syndrome and healthy women of reproductive age. Akush Ginekol (Sofiia). 2013;52:16-23.

World Health Organization, Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. 2000;1:17-20.

Lim, S.S., Davies, M.J., Norman, R.J., Moran, L.J. Overweight, obesity, and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:618-637.

Morshed, M., Banu, H., Akhtar, N., Sultana, T., Begum, A., Zamilla, M., et al., Luteinizing hormone to follicle-stimulating hormone ratio significantly correlates with androgen level and manifestations are more frequent with hyperandrogenemia in women with polycystic ovary syndrome. J Endocrinol Metab. 2021;11:14-21.

Laven, J. S., Mulders, A.G., Visser, J.A., Themmen, A.P., DeJong, F.H., Fauser, B.C. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318-323.

Abbara, A., Eng, P.C., Phylactou, M., Clarke, S.A., Hunjan, T., Roberts, R., et al., Anti-Mullerian hormone (AMH) in the diagnosis of menstrual disturbance due to polycystic ovarian syndrome. Front Endocrinol (Lausanne). 2019;10:1-9.

Pigny, P., Merlen, E., Robert, Y., Cortet-Rudelli, C., Decanter, C., Jonard, S., et al., Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957-5962.

Mahajan, N., Kaur, J. Establishing an anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using the automated anti-Müllerian hormone assay. J Hum Reprod Sci. 2019;12:104-113.

Ahmed, N., Batarfi, A.A., Bajouh, O.S., Bakhashab, S. Serum anti-Müllerian hormone in the diagnosis of polycystic ovary syndrome in association with clinical symptoms. Diagnostics (Basel). 2019;9:1-6.

Lujan, M.E., Chizen, D.R., Pierson, R.A. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 2008;30:671-679.

Amer, S.A., Li, T.C., Bygrave, C., Sprigg, A., Saravelos, H., Cooke, I.D. An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries. Hum Reprod. 2002;17:1616-1622.

Hehenkamp, W.J., Looman, C.W., Themmen, A.P., DeJong, F.H., TeVelde, E.R., Broekmans, F.J. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006; 91:4057-4063.

Catteau-Jonard, S., Bancquart, J., Poncelet, E., Lefebvre-Maunoury, C., Robin, G., Dewailly, D. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound Obstet Gynecol. 2012;40:223-229.

Saxena, U., Ramani, M., Singh, P. Role of AMH as a diagnostic tool for polycystic ovarian syndrome. J Obstet Gynaecol India. 2018;68:117-122.